Pliant Therapeutics, Inc. (PLRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 26.05 |
| Open | 25.76 |
| Bid | 25.52 x 800 |
| Ask | 25.55 x 800 |
| Day's Range | 25.30 - 26.20 |
| 52 Week Range | 3.96 - 36.64 |
| Volume | |
| Avg. Volume | 814,770 |
| Market Cap | 1.494B |
| Beta (5Y Monthly) | 1.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.57 |
| Earnings Date | May 08, 2023 - May 12, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.64 |
- GlobeNewswire
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg doseSOUTH SAN FRANCISCO, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced that, following a positive independent Data Safety Monitoring Board (DSMB) safe
- Simply Wall St.
Pliant Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
Pliant Therapeutics ( NASDAQ:PLRX ) Full Year 2022 Results Key Financial Results Net loss: US$123.3m (loss widened by...
- Zacks
Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
